Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2017 Dec 6;16:177. doi: 10.1186/s12943-017-0745-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — CR-PDX cell lines are amenable to in vivo preclinical applications. a. Re-implanted CR-HLXF-036LN and CR-LG0567F cells formed tumors in NSG mice (open symbols) and maintained growth kinetics of parental tumor (closed symbols). CR-HLXF-036LN maintained sensitivity to Savolitinib (25 mg/kg, QD, n = 2) and CR-LG0567F maintained sensitivity to Selumetinib (25 mg/kg, BID, n = 3) similar to parental tumors (dotted lines, n = 10 for HLXF-036LN and n = 9 for LG0567F). Mean ± error shown for each model. b Implanted CR-PDX tumors maintain pharmacodynamic response to targeted agents, similar to parental tumors. c Subcutaneously implanted CR-PDX cells produce tumors with histology similar to parental PDX tumor. Representative images shown (n = 2)